UK life science investment - Jefferies’ MD of Global Healthcare Investment Banking [video]

During the recent HealthEx London forum at One George Street, Westminster, Biotech and Money had the opportunity to interview several CEOs from highly successful, leading biotech and investment firms.

In this video we talk to Dr Gil Bar-Nahum, Managing Director for the Global Healthcare Investment Banking Group at Jefferies & Co. With fifteen years’ experience working in European, Asian and Israeli life sciences investment, Gil has held a variety of directorial positions in UBS’s healthcare and life sciences divisions.

With his PhD work twice published in respected scientific journal Cell, Gil’s breadth of knowledge covers microbiology, biochemistry and medical sciences as well as investment banking in the life sciences sector.

In the past year, he has raised over US$500 million in growth capital for life sciences companies in Israel, and has assisted in the IPOs for numerous companies, including Kamada, Enzymotec, Lumenis and Mediwound. In 2013 he was named Israeli Financial Advisor of the Year.

In this video interview, we ask Gil what his predictions are for the future of biotech investment in the UK, what the biggest game changers are to the sector, and what the biggest challenges are for modern day life science company CEOs.

Click the image to view the short video.

Other videos in this series includes short interviews with Jim Phillips, CEO, Midatech Pharma, Justin Gover, CEO, GW Pharmaceuticals, Neil Murray, CEO, Redx Pharma and Wolfgang Rencken, CEO, Sphere Medical.

To enquire about involvement in our 2016 HealthEx London forum, taking place during Biotech and Money London 2016 on 2-3 February as a Partner click here. If you are interested in being selected as a delegate click here.

Tags :

Leave a comment